Executive summary: It's wrong not to test: The case for universal, frequent rapid COVID-19 testing

Rapid Tests Working Group

doi:10.1016/j.eclinm.2021.100759

Executive summary: It's wrong not to test: The case for universal, frequent rapid COVID-19 testing

Rapid Tests Working Group

Health Solutions, College of (CHS)

Research output: Contribution to journal › Comment/debate › peer-review

9 Scopus citations

Original language	English (US)
Article number	100759
Journal	EClinicalMedicine
Volume	33
DOIs	https://doi.org/10.1016/j.eclinm.2021.100759
State	Published - Mar 2021

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1016/j.eclinm.2021.100759

Cite this

@article{250da45be74241f48d14723ed259c350,

title = "Executive summary: It's wrong not to test: The case for universal, frequent rapid COVID-19 testing",

author = "{Rapid Tests Working Group} and Maureen Johnson-Le{\'o}n and Caplan, {Arthur L.} and Louise Kenny and Iain Buchan and Leah Fesi and Phoebe Olhava and {Nsobila Alugnoa}, Desmond and Aspinall, {Mara G.} and Emily Costanza and Brianna Desharnais and Corinne Price and Jon Frankle and Jonas Binding and Ramirez, {Cherie Lynn}",

note = "Funding Information: The authors declare that they do not have any manifest conflict of interest. Dr. Buchan reports personal fees and other from his service as Chief Data Scientist Advisor to AstraZeneca and a grant from the National Institute for Health Research (NIHR), all outside the submitted work. Ms. Aspinall reports that she is compensated for her service on the Boards of Directors of both Orasure and Abcam as well as for serving as an Advisor to Cepheid. Dr. Binding reports that he works for Robert Bosch GmbH. There is a separate division within the company producing and selling rapid PCR tests for SARS-CoV-2 ({"}Vivalytics{"}). He declares that he has no work ties with that team. Funding Information: We thank the following collaborators for their invaluable contributions to this work: Emerging Infectious Disease (EID) Policy Researcher Mary Marshall, Mr. Ishaan Desai, Mr. Steven S. Ross, Dr. Joseph DeRisi, Dr. Robert Klitzman, Dr. Irene Petersen, Dr. Chris Said, & Dr. Michael Mina. Ms. Costanza was supported by the Simmons University Fund for Undergraduate Research and Creative Endeavors. Ms. Desharnais was supported by the Summer Undergraduate Research Program at Simmons (SURPASs). This commentary is dedicated to the practitioners, researchers, policymakers, and everyday people whose courage and perseverance have made possible the body of knowledge that informs our work. ",

year = "2021",

month = mar,

doi = "10.1016/j.eclinm.2021.100759",

language = "English (US)",

volume = "33",

journal = "EClinicalMedicine",

issn = "2589-5370",

publisher = "Lancet Publishing Group",

}

TY - JOUR

T1 - Executive summary

T2 - It's wrong not to test: The case for universal, frequent rapid COVID-19 testing

AU - Rapid Tests Working Group

AU - Johnson-León, Maureen

AU - Caplan, Arthur L.

AU - Kenny, Louise

AU - Buchan, Iain

AU - Fesi, Leah

AU - Olhava, Phoebe

AU - Nsobila Alugnoa, Desmond

AU - Aspinall, Mara G.

AU - Costanza, Emily

AU - Desharnais, Brianna

AU - Price, Corinne

AU - Frankle, Jon

AU - Binding, Jonas

AU - Ramirez, Cherie Lynn

N1 - Funding Information: The authors declare that they do not have any manifest conflict of interest. Dr. Buchan reports personal fees and other from his service as Chief Data Scientist Advisor to AstraZeneca and a grant from the National Institute for Health Research (NIHR), all outside the submitted work. Ms. Aspinall reports that she is compensated for her service on the Boards of Directors of both Orasure and Abcam as well as for serving as an Advisor to Cepheid. Dr. Binding reports that he works for Robert Bosch GmbH. There is a separate division within the company producing and selling rapid PCR tests for SARS-CoV-2 ("Vivalytics"). He declares that he has no work ties with that team. Funding Information: We thank the following collaborators for their invaluable contributions to this work: Emerging Infectious Disease (EID) Policy Researcher Mary Marshall, Mr. Ishaan Desai, Mr. Steven S. Ross, Dr. Joseph DeRisi, Dr. Robert Klitzman, Dr. Irene Petersen, Dr. Chris Said, & Dr. Michael Mina. Ms. Costanza was supported by the Simmons University Fund for Undergraduate Research and Creative Endeavors. Ms. Desharnais was supported by the Summer Undergraduate Research Program at Simmons (SURPASs). This commentary is dedicated to the practitioners, researchers, policymakers, and everyday people whose courage and perseverance have made possible the body of knowledge that informs our work.

PY - 2021/3

Y1 - 2021/3

UR - http://www.scopus.com/inward/record.url?scp=85101068271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85101068271&partnerID=8YFLogxK

U2 - 10.1016/j.eclinm.2021.100759

DO - 10.1016/j.eclinm.2021.100759

M3 - Comment/debate

AN - SCOPUS:85101068271

SN - 2589-5370

VL - 33

JO - EClinicalMedicine

JF - EClinicalMedicine

M1 - 100759

ER -

Executive summary: It's wrong not to test: The case for universal, frequent rapid COVID-19 testing

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this